Key Takeaways
- • 9amHealth secured $26 million in Series B funding, led by Define Ventures with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures.
- • The funding underscores continued investor appetite for virtual specialty care platforms addressing gaps in remote healthcare delivery.
- • The round brings together a diverse syndicate of healthcare-focused and venture investors, indicating broad confidence in the company's market positioning.
Summary
9amHealth, a virtual specialty care platform based in San Diego, announced $26 million in Series B funding on May 13, 2026. Define Ventures led the round, with additional support from three new investors: SemperVirens VC, Catalio Capital Management, and NewHealth Ventures.
The funding demonstrates sustained institutional interest in telehealth and virtual care infrastructure, particularly within specialty medicine segments where geographic and access constraints remain significant barriers for patients. The syndicate composition—featuring both dedicated healthcare investors and broader venture capital firms—reflects confidence in the company's ability to capture market share in an increasingly competitive virtual care landscape.
While the announcement does not provide detailed information regarding capital allocation, revenue metrics, or specific strategic initiatives planned for the deployment of these funds, the Series B milestone positions 9amHealth for potential expansion in clinical capabilities, technology infrastructure, or geographic reach. The participation of multiple healthcare-specialized investors suggests validation of 9amHealth's market opportunity and operational execution to date.
The funding demonstrates sustained institutional interest in telehealth and virtual care infrastructure, particularly within specialty medicine segments where geographic and access constraints remain significant barriers for patients. The syndicate composition—featuring both dedicated healthcare investors and broader venture capital firms—reflects confidence in the company's ability to capture market share in an increasingly competitive virtual care landscape.
While the announcement does not provide detailed information regarding capital allocation, revenue metrics, or specific strategic initiatives planned for the deployment of these funds, the Series B milestone positions 9amHealth for potential expansion in clinical capabilities, technology infrastructure, or geographic reach. The participation of multiple healthcare-specialized investors suggests validation of 9amHealth's market opportunity and operational execution to date.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.